139 related articles for article (PubMed ID: 9209663)
21. Expression of glutathione S-transferase-pi in human ovarian cancer as an indicator of resistance to chemotherapy.
Hamada S; Kamada M; Furumoto H; Hirao T; Aono T
Gynecol Oncol; 1994 Mar; 52(3):313-9. PubMed ID: 8157188
[TBL] [Abstract][Full Text] [Related]
22. Multidrug resistance-associated biomarkers PGP, GST-pi, Topo-II and LRP as prognostic factors in primary ovarian carcinoma.
Lu D; Shi HC; Wang ZX; Gu XW; Zeng YJ
Br J Biomed Sci; 2011; 68(2):69-74. PubMed ID: 21706917
[TBL] [Abstract][Full Text] [Related]
23. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.
van der Zee AG; van Ommen B; Meijer C; Hollema H; van Bladeren PJ; de Vries EG
Br J Cancer; 1992 Nov; 66(5):930-6. PubMed ID: 1419639
[TBL] [Abstract][Full Text] [Related]
24. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
25. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
26. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients.
Surowiak P; Materna V; Kaplenko I; Spaczyński M; Dietel M; Lage H; Zabel M
Virchows Arch; 2005 Sep; 447(3):626-33. PubMed ID: 15968547
[TBL] [Abstract][Full Text] [Related]
27. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
28. Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.
Pereira D; Assis J; Gomes M; Nogueira A; Medeiros R
Eur J Clin Pharmacol; 2016 May; 72(5):545-53. PubMed ID: 26803611
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
30. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
31. Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer.
Howells RE; Dhar KK; Hoban PR; Jones PW; Fryer AA; Redman CW; Strange RC
Int J Gynecol Cancer; 2004; 14(2):242-50. PubMed ID: 15086723
[TBL] [Abstract][Full Text] [Related]
32. [Expression of glutathione S-transferase pi and numerical aberration of chromosome 11 in human ovarian cancer as a prognostic indicator].
Yokoyama Y; Fukushi Y; Kunugi T; Maruyama H; Sato S; Saito Y
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Feb; 48(2):118-24. PubMed ID: 8718547
[TBL] [Abstract][Full Text] [Related]
33. Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients.
Morari EC; Lima AB; Bufalo NE; Leite JL; Granja F; Ward LS
J Cancer Res Clin Oncol; 2006 Aug; 132(8):521-8. PubMed ID: 16788846
[TBL] [Abstract][Full Text] [Related]
34. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
35. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
36. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer.
Tanner B; Hengstler JG; Dietrich B; Henrich M; Steinberg P; Weikel W; Meinert R; Kaina B; Oesch F; Knapstein PG
Gynecol Oncol; 1997 Apr; 65(1):54-62. PubMed ID: 9103391
[TBL] [Abstract][Full Text] [Related]
37. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
38. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer.
Toffoli G; Russo A; Gallo A; Cernigoi C; Miotti S; Sorio R; Tumolo S; Boiocchi M
Int J Cancer; 1998 Apr; 79(2):121-6. PubMed ID: 9583724
[TBL] [Abstract][Full Text] [Related]
39. Long-term prognostic factors for chemotherapy of ovarian cancer.
Muso H
Osaka City Med J; 1998 Dec; 44(2):155-71. PubMed ID: 10097596
[TBL] [Abstract][Full Text] [Related]
40. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
